NCT04265716

Topical L. Reuteri in Children With Atopic Dermatitis

Topical Lactobacillus Reuteri DSM 17938 to Evaluate Safety and Efficacy on Children With Mild or Moderate Atopic Dermatitis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 102 (estimated)
• Sponsor: Innovacion y Desarrollo de Estrategias en Salud · Academic / Other
• Sex: All
• Age: 1 Year – 8 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the safety and efficacy of the probiotic L. reuteri vs control product as an adjuvant for improving the skin appearance of children with mild or moderate atopic dermatitis. All children will receive the standard of care. Half of the children will receive topical L. reuteri in emollient, while the other half will receive the standard of care plus control product

Detailed description

AD if a very frequent allergic skin disorders in children. Produce a negative significant impact on quality of life and related costs. Recently the changes of skin microbiota had been related with inadequate evolution of atopic dermatitis. L. reuteri had been identified with some effect to reduce skin inflammation and help to modulate inflammatory pathways on skin. Investigators expect using topical L. reuteri as adjuvant some improvement on skin appearance due to the mode of action previous referenced additionally to some potential changes on microbiome

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
OTHER	Topical L. reeuteri	Tubes with ointment containing L. reuteri DSM17938

Timeline

• Start date: 2020-02-13
• Primary completion: 2020-05-13
• Completion: 2020-10-30
• First posted: 2020-02-12
• Last updated: 2020-03-17

Locations

1 site across 1 country: Mexico